13F Holdings
中文EN

KPRX KIORA PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1372514 · Fiscal year ends 12/31

Financial factors as of 2025-03-31 (2025Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-99.9%
TTM net income YoY-529.2%
TTM EPS YoY84.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-55,210.8%
Net margin-60,257.3%
FCF margin—
EBITDA margin-55,137.5%

Returns

ROE-41.1%
ROA-31.5%
ROIC (approx.)-74.1%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets30.3%
Debt / equity0.00x
Current ratio5.14x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-11.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$16.02M$0—$0
R&D expense$10.78M$7.84M$4.03M$3.45M$5.35M
SG&A expense$5.75M$5.54M$4.66M$8.28M$5.32M
Operating income-$12.83M$4.51M-$12.59M-$12.31M-$14.24M
Interest expense$19,960$21,446$11,132$8,599$6,851
Pretax income-$12.12M$5.66M-$12.42M-$13.70M-$13.96M
Income tax-$1.28M$2.07M$90,319-$113,010-$192,603
Net income-$10.84M$3.59M-$12.51M-$13.58M-$13.77M
EBITDA-$12.81M$4.53M-$12.54M-$12.27M-$14.19M
EPS (basic)-2.600.93-24.25-18.55-57.12
EPS (diluted)-2.640.87-24.25-18.55-57.12
Weighted avg. shares (diluted)4.10M4.13M538,007732,303241,099
Balance sheet
Cash & equivalents$8.70M$3.80M$2.46M$6.01M$7.90M
Short-term investments$8.39M$23.00M$0——
Receivables$1.52M$601,197$0——
Current assets$21.75M$29.71M$4.74M$7.68M$8.99M
PP&E, net$91,672$5,232$8,065$55,177$73,999
Goodwill———$0$0
Intangibles$2.06M$6.69M$8.81M$10.74M$10.77M
Total assets$24.25M$36.48M$13.71M$18.68M$20.13M
Current liabilities$3.63M$6.01M$1.63M$3.27M$1.61M
Total liabilities$8.13M$10.72M$7.60M$7.27M$5.55M
Shareholders' equity$16.13M$25.76M$6.11M$11.41M$14.58M
Shares outstanding3.76M3.00M856,1821.80M316,599
Cash flow statement
Operating cash flow-$9.96M$8.56M-$9.56M-$10.43M-$10.68M
Capital expenditure$110,789$6,256$0$0$63,865
Free cash flow-$10.07M$8.55M-$9.56M-$10.43M-$10.74M
Investing cash flow$14.43M-$22.66M$0$6,375-$157,020
Financing cash flow$265,655$15.50M$5.97M$8.62M$17.58M
Depreciation & amortization$24,801$19,205$51,798$41,609$45,296
Stock-based compensation$900,236$656,593$754,944$462,450$842,475

Free plan shows the latest 5 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.